---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-015318"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:36:00.198434+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics regains Nasdaq compliance on audit committee composition

## Summary
- Received Nasdaq letter on March 22, 2024, confirming regained compliance with Listing Rule 5605.
- Non-compliance was previously disclosed on Jan 17, 2024, due to lack of three independent directors.
- Compliance restored on March 20, 2024, with appointment of Rodney Nussbaum to Audit Committee.
- No further deficiencies; shares continue trading on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001140361-24-015318
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036124015318/0001140361-24-015318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036124015318/ef20025179_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-015318
- JSON: https://secwatch.observer/filing/0001140361-24-015318.json
- Plain text: https://secwatch.observer/filing/0001140361-24-015318.txt

## Key facts
- Listing & Compliance Notices
  GYRE THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding audit committee (rules 5605).
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: audit committee
  - Rules: 5605
  source text: March 22, 2024, Gyre Therapeutics, Inc. (the “ Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the audit committee composition requirements as set forth in Nasdaq Listing Rule 5605 for continued listing on The Nasdaq Capital Market. As previously disclosed, on January 17, 2024, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5605 because its Audit Committee was not comprised of at least three “independent directors” (as defined in Nasdaq Listing Rule 5605(a)(2)). The C
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036124015318/0001140361-24-015318-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.